Daljeet Saluja, MD
Family Medicine · Baltimore, MDNPI 1326011024
Payments from drug & device makers
Across 869 payments — averaging $72.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$38K
- Novo Nordisk$9K
- Sanofi-aventis U.S. LLC$3K
- GSK$2K
- Dexcom, Inc.$2K
- Bayer$959
- plus $8K from 46 others
What the payments were for
- Consulting fees$5,3448%
- Speaking & faculty fees$33,32353%
- Travel & lodging$2,4594%
- Food & beverage$21,69234%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$34,016
- DEXCOM G6 TRANSMITTER$1,373
- FreeStyle Libre 2$384
- Kerendia$282
- FREESTYLE LIBRE 3$276
- SOLIQUA 100/33$271
- DEXCOM G7 GSS (161)$252
- Korlym$247
- AREXVY$242
- TOUJEO$237
- Ozempic$225
- BREZTRI$215
- DEXCOM STELO GLUCOSE BIOSENSOR$145
- TEZSPIRE$135
- TZIELD$131
- RYBELSUS$116
- GVOKE HYPOPEN$113
- GEMTESA$110
- Yupelri$110
- KRYSTEXXA$110
How this compares
$63,038 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $222,436 |
| EliquisApixaban | 183 | $211,063 |
| OzempicSemaglutide | 143 | $195,812 |
| JardianceEmpagliflozin | 147 | $159,120 |
| FarxigaDapagliflozin Propanediol | 133 | $130,417 |
| MounjaroTirzepatide | 77 | $120,742 |
| JanuviaSitagliptin Phosphate | 61 | $74,843 |
| RybelsusSemaglutide | 30 | $64,863 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 59 | $52,332 |
| LinzessLinaclotide | 39 | $47,399 |
| EntrestoSacubitril/Valsartan | 32 | $44,214 |
| XareltoRivaroxaban | 42 | $42,709 |
| TrulicityDulaglutide | 23 | $38,392 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 38 | $31,770 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $24,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,246 | $264,181224 claims |
| Novo NordiskOzempic, Rybelsus | $8,526 | $260,676173 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi, Tradjenta | $459 | $219,081220 claims |
| PfizerEliquis | $247 | $211,063183 claims |
| Lilly USA, LLCMounjaro, Trulicity | $766 | $159,133100 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $37,858 | $153,922161 claims |
| MerckJanuvia | $432 | $74,84361 claims |
| AbbVieLinzess, Namzaric | $483 | $55,63651 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,187 | $52,33259 claims |
| NovartisEntresto | $597 | $44,21432 claims |
| Johnson & JohnsonXarelto | $66 | $42,70942 claims |
| Astellas Pharma US IncMyrbetriq | $458 | $21,19218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Baltimore
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Fernando PorterBaltimore$54K
- Richard ColganBaltimore$31K
- Stacy GarrettBaltimore$20K
- Nishant ShahBaltimore$17K
- Diaa MikhailBaltimore$15K
- Yaniv BergerBaltimore$13K
- Stephen OngOxon Hill$5.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.